Format

Send to

Choose Destination
See comment in PubMed Commons below
Future Oncol. 2009 Nov;5(9):1349-61. doi: 10.2217/fon.09.119.

Nimotuzumab in pediatric glioma.

Author information

1
The Hospital for Sick Children, Division for Haematology/Oncology, Toronto, Canada.

Abstract

High-grade gliomas and diffuse brainstem gliomas carry a very poor prognosis despite current therapies, and account together for the largest number of deaths in children with brain tumors. Many of these tumors have been found to overexpress the EGF receptor (EGFR). Nimotuzumab (h-R3) is a humanized monoclonal antibody against the EGFR, and consequently inhibits tyrosine kinase activation. In vitro and in vivo studies have supported the antiproliferative, antiangiogenic, pro-apoptotic and radiosensitizing activities of nimotuzumab. Emerging trials suggest a promising role for nimotuzumab as a therapeutic agent in patients with high-grade gliomas. This review attempts to provide a context for the evolving interest and evidence for nimotuzumab in pediatric glioma.

PMID:
19903064
DOI:
10.2217/fon.09.119
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center